Navigator Medicines, a biotech company focused on advancing biologics for immune regulation, announced a $100 million Series A financing and the in-licensing of NAV-240 and an OX40L-targeted portfolio from IMBiologics Corp. NAV-240, previously known as IMB101, is a clinical-stage bispecific antibody targeting OX40L and TNFα, key players in several inflammatory diseases. This dual-targeting approach aims to improve efficacy in treating complex autoimmune conditions. The financing round was co-led by RA Capital Management and Forbion.
Dr. Dana McClintock, CMO of Navigator Medicines, expressed excitement about advancing NAV-240 in the clinic, emphasizing the potential impact on patients with autoimmune diseases. The funding will accelerate NAV-240’s development and other pipeline projects, with additional clinical studies planned in the coming months.
Wouter Joustra, General Partner at Forbion, highlighted the partnership’s potential to realize NAV-240’s full therapeutic potential, noting Navigator’s expertise and resources. In addition to the financing, Mr. Joustra and Dr. Andrew Levin, Partner and Managing Director at RA Capital Management, will join Navigator’s Board of Directors, with Dr. Levin noting the opportunity to advance therapeutic standards and transform patient care.
About Navigator Medicines:
Founded in 2024 as a subsidiary of Sera Medicines, Navigator Medicines specializes in biologics for immune regulation and restoration, aiming to develop new therapies for autoimmune diseases.
About Forbion:
Forbion is a global venture capital firm with expertise in life sciences, managing €3.2 billion across multiple fund strategies. With a focus on biotech and human health, Forbion also invests in sustainable solutions through its BioEconomy fund.
About RA Capital Management:
RA Capital Management is an investment manager focused on healthcare, life sciences, and planetary health companies, supporting them from inception through commercialization. Their approach is driven by evidence-based investing and supported by their Tech Atlas research division and RA Ventures (RAVen) company creation team.
